Angela Gillespie, former VP of marketing for NeuWave Medical, has returned to W20 Group as chief strategy officer of its global MedTech practice, a new post overseeing its medical device business across the firm's agencies.
Gillespie started San Francisco-based W20's medical device practice in 2007. She will be based in Minneapolis with a mandate to double the firm's partnerships with medtech companies over the next five years.
W20 chief client officer Jennifer Gottlieb said factors like personalized medicine, digital health and medical device and diagnostics have the medtech sector poised for rapid growth over the next decade. She said Gillespie knows the sector "cold" and will "galvanize" the firm's offering.
Prior to Neuwave, which was acquired by Johnson & Johnson in April, Gillespie was senior market development leader for Covidien's peripheral and venous vascular business units, since acquired by Medtronic.
On the agency side, she earlier advised medical device clients at MDMC and was a VP at FischerHealth and account manager at Porter Novelli.
Jeffrey Sturchio is joining Finn Partners’ health policy and impact group as senior advisor to counsel clients on the issues shaping global health and innovation access.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
